CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Wang, Xiyong
    Zhu, Xiaoli
    Zhang, Hongming
    Fan, Xiaobo
    Xue, Xiulei
    Chen, Yan
    Ding, Chenbo
    Zhao, Jianwen
    Wu, Guoqiu
    JOURNAL OF CANCER, 2017, 8 (14): : 2846 - 2853
  • [42] Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
    Lee, Seung Hyeun
    Choi, Sue In
    Lee, Ji Sung
    Kim, Chul Hwan
    Jung, Won Jai
    Lee, Eun Joo
    Min, Kyung Hoon
    Hur, Gyu Young
    Lee, Seung Heon
    Lee, Sung Yong
    Kim, Je Hyeong
    Lee, Sang Yeub
    Shin, Chol
    Shim, Jae Jeong
    Kang, Kyung Ho
    In, Kwang Ho
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 141 - 149
  • [43] NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Chang, Boksoon
    Park, Myung Jae
    Choi, Sue In
    In, Kwang Ho
    Kim, Chul Hwan
    Lee, Seung Hyeun
    ONCOTARGETS AND THERAPY, 2017, 10 : 4625 - 4633
  • [44] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Chen, Jianli
    Emara, Nashwa
    Solomides, Charalambos
    Parekh, Hemant
    Simpkins, Henry
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1103 - 1111
  • [45] Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
    Yin, Ji-Ye
    Huang, Qiong
    Zhao, Ying-Chun
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    PLOS ONE, 2012, 7 (06):
  • [46] A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer
    Ballas, MS
    Dennis, PA
    CANCER BIOLOGY & THERAPY, 2005, 4 (12) : 1316 - 1317
  • [47] Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy
    Li, Xiaoying
    Shao, Minhua
    Wang, Shiming
    Zhao, Xueying
    Chen, Hongyan
    Qian, Ji
    Song, Xiao
    Wang, Jiucun
    Jin, Li
    Wu, Junjie
    Li, Qiang
    Bai, Chunxue
    Han, Baohui
    Gao, Zhiqiang
    Lu, Daru
    TUMOR BIOLOGY, 2014, 35 (11) : 11159 - 11170
  • [48] DECREASE OF CIRCULATING TUMOR CELLS ASSOCIATES WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, BUT NOT WITH SMALL CELL LUNG CANCER
    Gauler, Thomas C.
    Theegarten, Dirk
    Parr, Annette
    Schuhr, Ivonne
    Schmid, Kurt W.
    Eberhardt, Wilfried
    Schuler, Martin
    Hoffmann, Andreas-Claudius
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1114 - S1114
  • [49] Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer
    Podmaniczky, Eszter
    Fabian, Katalin
    Papay, Judit
    Puskas, Rita
    Gyulai, Marton
    Furak, Jozsef
    Tiszlavicz, Laszlo
    Losonczy, Gyoergy
    Timar, Jozsef
    Moldvay, Judit
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (02) : 423 - 431
  • [50] Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Wenheng
    Mao, Yan
    Zhan, Yongzi
    Huang, Jianheng
    Wang, Xiangping
    Luo, Penghui
    Li, Li
    Mo, Dunchang
    Liu, Qiong
    Xu, Huimin
    Huang, Changjie
    ONCOLOGY LETTERS, 2016, 11 (01) : 723 - 730